Literature DB >> 9084432

Matrix metalloproteinases in dog brains exhibiting Alzheimer-like characteristics.

G P Lim1, M J Russell, M J Cullen, Z A Tökés.   

Abstract

We have previously reported that the amount of the neuronal matrix metalloproteinase (MMP) MMP-9, capable of cleaving beta-amyloid,-40 predominantly at Leu34-Met35, is increased in a latent form in hippocampal specimens from AD patients and have suggested that the lack of activation of this enzyme may contribute to the deposition of beta-amyloid in plaques. The current study addresses whether similar matrix proteinases are detectable in amyloid-positive and -negative brain specimens of aged beagles. Using quantitative zymography, three major neutral proteinases with molecular masses of 60, 95, and 280 kDa were readily detected. These enzymes have the characteristics of MMPs because they were inhibited by EDTA and 1, 10-phenanthroline, and their activities were restored by addition of both Ca2+ and Zn2+. The 95- and 280-kDa proteinases cross-reacted with specific monoclonal antibodies to human MMP-9 (gelatinase B; EC 3.4. 24.35). Canine MMP-9 was latent because activation by organomercurial treatment resulted in a characteristic decrease in molecular mass. Statistical analysis revealed no difference in the 60-kDa proteinase activity in amyloid-positive and -negative brain specimens. However, significantly increased amounts of latent MMP-9 were observed in amyloid-positive brain specimens (p < or = 0.05) compared with amyloid-negative brain specimens. The observations document that changes in MMP-9 expression in amyloid-positive beagle brains are similar to those reported in the human Alzheimer's disease hippocampus and suggest the possibility that insufficient activation of MMP-9 may contribute to beta-amyloid accumulation, a hypothesis that needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084432     DOI: 10.1046/j.1471-4159.1997.68041606.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus.

Authors:  Arek Szklarczyk; Joanna Lapinska; Marcin Rylski; Ronald D G McKay; Leszek Kaczmarek
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

3.  Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.

Authors:  Khaled H Elfakhri; Quoc-Viet Duong; Courtney Langley; Ashley Depaula; Youssef M Mousa; Trista Lebeouf; Courtney Cain; Amal Kaddoumi
Journal:  Neuroscience       Date:  2018-03-26       Impact factor: 3.590

4.  Proteolytic activation of matrix metalloproteinase-9 in skin wound healing is inhibited by alpha-1-antichymotrypsin.

Authors:  Yuan-Ping Han; Chunli Yan; Warren L Garner
Journal:  J Invest Dermatol       Date:  2008-04-10       Impact factor: 8.551

5.  Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease.

Authors:  Ali Aijaz Hussain; Yunhee Lee; Jin-Jun Zhang; Paul T Francis; John Marshall
Journal:  J Neurodegener Dis       Date:  2017-01-18

Review 6.  Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction.

Authors:  John W Wright; Joseph W Harding
Journal:  Neural Plast       Date:  2010-02-10       Impact factor: 3.599

7.  Identification of matrix metalloproteinase-2 and -9 activities within intestinal mucosa of clinically healthy beagle dogs.

Authors:  Mohsen Hanifeh; Minna M Rajamäki; Laura Mäkitalo; Pernilla Syrjä; Satu Sankari; Susanne Kilpinen; Thomas Spillmann
Journal:  J Vet Med Sci       Date:  2014-04-18       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.